These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 15570357)

  • 1. A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting.
    Madan M; Labinaz M; Cohen EA; Buller CE; Cantor WJ; Seidelin P; Ducas J; Carere RG; Natarajan MK; Pieper KS; Hafley GE; O'Shea JC; Kitt MM; Califf RM; Tcheng JE;
    Can J Cardiol; 2004 Nov; 20(13):1343-9. PubMed ID: 15570357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
    Granada JF; Kleiman NS
    Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
    Puma JA; Banko LT; Pieper KS; Sacchi TJ; O'Shea JC; Dery JP; Tcheng JE
    J Am Coll Cardiol; 2006 Feb; 47(4):715-8. PubMed ID: 16487833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.
    O'Shea JC; Hafley GE; Greenberg S; Hasselblad V; Lorenz TJ; Kitt MM; Strony J; Tcheng JE;
    JAMA; 2001 May; 285(19):2468-73. PubMed ID: 11368699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of operator and institutional volume on clinical outcomes after percutaneous coronary interventions performed in Canada and the United States: a brief report from the Enhanced Suppression of the Platelet glycoprotein IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) study.
    Madan M; Nikhil J; Hellkamp AS; Pieper KS; Labinaz M; Cohen EA; Buller CE; Cantor WJ; Seidelin P; Ducas J; Carere RG; Natarajan MK; O'Shea JC; Tcheng JE;
    Can J Cardiol; 2009 Aug; 25(8):e269-72. PubMed ID: 19668787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.
    O'Shea JC; Buller CE; Cantor WJ; Chandler AB; Cohen EA; Cohen DJ; Gilchrist IC; Kleiman NS; Labinaz M; Madan M; Hafley GE; Califf RM; Kitt MM; Strony J; Tcheng JE;
    JAMA; 2002 Feb; 287(5):618-21. PubMed ID: 11829701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.
    Labinaz M; Kaul P; Harrington RA; Chang WC; Kleiman NS; Simoons ML; Boersma E; Akkerhuis KM; Califf RM; Armstrong PW;
    Can J Cardiol; 2004 Jun; 20(8):773-8. PubMed ID: 15229770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.
    Fernandes LS; Tcheng JE; O'Shea JC; Weiner B; Lorenz TJ; Pacchiana C; Berdan LG; Maresh KJ; Joseph D; Madan M; Mann T; Kilaru R; Hochman JS; Kleiman NS;
    J Am Coll Cardiol; 2002 Sep; 40(6):1085-91. PubMed ID: 12354432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial).
    Labinaz M; Madan M; O'Shea JO; Kilaru R; Chin W; Pieper K; McGuire DK; Saucedo JF; Talley JD; Lui H; Kitt MM; Califf RM; Tcheng JT;
    Am J Cardiol; 2002 Sep; 90(6):585-90. PubMed ID: 12231081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
    Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.
    ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
    Lancet; 2000 Dec; 356(9247):2037-44. PubMed ID: 11145489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine use of glycoprotein IIb/IIIa inhibitor therapy is associated with an improved in-hospital outcome after percutaneous coronary intervention: Insights from a large, prospective, single-centre registry.
    Jackevicius CA; Pinto R; Daly P; Mackie K; Dzavik V
    Can J Cardiol; 2005 Jan; 21(1):27-32. PubMed ID: 15685299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial.
    Blankenship JC; Tasissa G; O'Shea JC; Iliadis EA; Bachour FA; Cohen DJ; Lui HK; Mann T; Cohen E; Tcheng JE;
    J Am Coll Cardiol; 2001 Sep; 38(3):653-8. PubMed ID: 11527612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
    Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
    Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial.
    Mehta RH; Kaul P; Lopes RD; Patel MR; Zheng Y; Pieper KS; Welsh RC; Armstrong PW; Granger CB
    Am Heart J; 2012 May; 163(5):797-803. PubMed ID: 22607857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era.
    Shishehbor MH; Topol EJ; Mukherjee D; Hu T; Cohen DJ; Stone GW; McClure R; Roffi M; Moliterno DJ;
    Am J Cardiol; 2006 Jun; 97(11):1585-90. PubMed ID: 16728219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Agarwal A; Vladutiu P; Feit A; Lapin R; Cavusoglu E
    J Invasive Cardiol; 2006 Nov; 18(11):521-6. PubMed ID: 17090813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of adjunctive eptifibatide therapy with percutaneous coronary intervention for acute myocardial infarction.
    Lev EI; Kornowski R; Teplisky I; Hasdai D; Rechavia E; Shor N; Battler A; Assali AR
    Int J Cardiovasc Intervent; 2005; 7(1):41-5. PubMed ID: 16019614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.